Pfizer Inc. $PFE is Willis Investment Counsel’s 9th Largest Position

Willis Investment Counsel raised its position in Pfizer Inc. (NYSE:PFE) by 5.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,818,508 shares of the biopharmaceutical company’s stock after acquiring an additional 100,571 shares during the period. Pfizer makes up approximately 2.1% of Willis Investment Counsel’s holdings, making the stock its 9th biggest holding. Willis Investment Counsel’s holdings in Pfizer were worth $43,790,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vermillion Wealth Management Inc. grew its stake in Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the last quarter. Eagle Capital Management LLC raised its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after buying an additional 390 shares during the last quarter. Delta Financial Advisors LLC raised its stake in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the last quarter. Pines Wealth Management LLC boosted its holdings in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD increased its holdings in shares of Pfizer by 1.0% during the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after acquiring an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3%

Pfizer stock opened at $26.88 on Tuesday. The firm has a market cap of $153.21 billion, a PE ratio of 35.37 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock’s 50 day simple moving average is $25.15 and its two-hundred day simple moving average is $26.20. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s payout ratio is 226.32%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PFE. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and cut their price objective for the company from $32.00 to $28.00 in a report on Monday, July 6th. UBS Group restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, BMO Capital Markets cut their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.